Table 1.
Patients´ characteristics (HU-treated patients).
| Patient no. | Gender | Age at diagnosis (years) | Disease duration before HU- treatment (months) | Therapies received before HU-treatment | CML-phase at start of HU-treatment | BCR-ABL1 mutations detected | WBC at HU-start (G/l) | HU dose (mg/day) | Duration of HU treatment (months) | Follow up - outcome and duration (months) |
|---|---|---|---|---|---|---|---|---|---|---|
| #1 | m | 41 | 22 | imatinib, cytarabin, 6-mercaptopurine, dasatinib | CP | T315I G250E E255K | 11.6 | 1500–2000 | 18 | HSCT MMR (20) |
| #2 | m | 65 | 108 | interferon-α, cytarabine, imatinib | CP | T315I | 9.6 | 1000–3000 | 11 | PD, † (13) |
| #3 | m | 53 | 104 | HSCT, DLI interferon-α imatinib, dasatinib, nilotinib | BP | T315I | 29.9 | 1500 | 2 | PD, † (2) |
| #4 | m | 51 | 92 | imatinib, dasatinib, nilotinib, interferon-α | CP | T315I E255K | 80.0 | 500–3000 | 4 | HSCT MMR |
HU, hydroxyurea; m, male; HSCT, allogenic hematopoietic stem cell transplantation; DLI, donor lymphocyte infusion; CP, chronic phase; BP, blast phase; MMR, major molecular response; PD, progressive disease.
†
Deceased.